Lobbying Information
Subject Matters
- Health
- Industry
- Science and Technology
Subject Matter Details
Legislative Proposal, Bill or Resolution, Policies or Program
- Patent Act with respect to Canada's Access to Medicines Regime (ss. 21.01-21.09)
Legislative Proposal, Bill or Resolution, Regulation
- Food and Drugs Act and Regulations, specifically with respect to the approval, regulation and life-cycle management of therapeutic products
Policies or Program
- Federal public drug plans, specifically the Non-Insured Health Benefits Program (Health Canada), with respect to decisions and policies that impact reimbursement of therapeutic products for plan beneficiaries
- Health Canada policy as it relates to pharmaceutical management strategies
- Patented Medicine Prices Review Board with respect to the regulation of pricing of patented drug products
- Science and Technology Strategy led by Industry Canada, particularly with respect to the life sciences priority under the S&T Strategy
Policies or Program, Regulation
- Health Canada Legislative and Regulatory Modernization program as related to the regulation and life-cycle management of therapeutic products and Orphan Drugs Regulatory Framework
- Health Canada policies with respect to authorization of subsequent entry biologics (SEBs) under the Food and Drugs Act and Regulations
Regulation
- Food and Drugs Act Regulations with respect to Data Protection under C.08.004.
- Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations.
- Patent Act as it relates to the regulation of intellectual property for therapeutic products
Communication Techniques
-
Written communication
-
Oral communication
The lobbyist has arranged or expects to arrange one or more meetings on behalf of the client between a public office holder and any other person in the course of this undertaking.
Government Institutions
-
Foreign Affairs and International Trade Canada (DFAITC)
-
Health Canada (HC)
-
House of Commons
-
Industry Canada
-
Patented Medicine Prices Review Board (PMPRB)
-
Prime Minister's Office (PMO)
-
Senate of Canada
Client Details
Government funding
No government funding was received during the last completed financial year.
Client Contact Information
Address:
4 Robert Speck Parkway
Mississauga, ON l4Z 1S1
Canada
Telephone number:
905-402-9926
Client representative
Rui Paiva, Commercial Director
Parent Company Information
- Eisai Co., Ltd.
-
4-6-10 Koishikawa, Bunkyo-ku
Tokyo 112-8088
Japan
- Eisai Inc.
-
100 Tice Blvd.
Woodcliffe Lake, NJ 07677
United States of America
Coalition Members Information
Eisai Limited is not a coalition.
Individual, organization or corporation with a Direct Interest Beneficiary Information
The activities of Eisai Limited are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.
Subsidiary Beneficiary Information
Eisai Limited does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Lobbyist Details
WILLIAM DEMPSTER
|
Public offices held
Business address:
130 Albert St.
Suite 408
OTTAWA, ON K1P 5G4
Canada
Telephone number:
613-614-0283
Fax number:
613-249-3645
Consultant Firm and Address
Firm:
3Sixty Public Affairs Inc. / 3Sixty Public Affairs Inc.
Address:
130 Albert Street
Suite 408
Ottawa, ON K1P 5G2
Canada
Telephone number:
613-800-8340
Fax number:
613-800-8343
